|
Endocyte initiates phase 1 trial of EC0489 for treatment of refractory or metastatic solid tumors
--May 5, 2009
Endocyte to present multiple abstracts at the 100th annual meeting of the american association for cancer research (AACR)
--April 17, 2009
Endocyte announces positive interim results from phase II clinical trial of EC145 in patients with advanced non-small cell lung cancer (NSCLC)
-- March 24, 2009
Endocyte begins phase II clinical trial of EC145 for treatment of women with ovarian cancer
-- February 19, 2009
Endocyte to Present at the BIO Investor Forum 2008
-- October 13, 2008
Endocyte Receives "Indiana Companies to Watch" Award
-- September 10, 2008
Endocyte Secures $15 Million Venture Debt Facility
-- January 25, 2008
Endocyte Announces Achievement of Milestone in Collaboration with Bristol-Myers Squibb
-- January 4, 2008
Endocyte to Present at the 26th Annual JPMorgan Healthcare Conference
-- January 3, 2008
Endocyte Announces License Agreement with R&D Biopharmaceuticals for the Development of Targeted Tubulysin Chemotherapeutic Agents
-- December 21, 2007
Chandra Lovejoy joins Endocyte as Director of Regulatory Affairs
-- December 17, 2007
Endocyte secures $15 million in Series C-3 round of financing
-- March 23, 2007
|